Outset Medical (OM)
NASDAQ:OM
OM Stock Chart & Stats
$4.10
-$0.10(-9.09%)
At close: 4:00 PM EST
$4.10
-$0.10(-9.09%)
Day’s Range― - ―
52-Week Range$3.00 - $21.98
Previous CloseN/A
Volume1.92M
Average Volume (3M)190.72K
Market Cap
$76.82M
Enterprise Value$146.42M
Total Cash (Recent Filing)$168.95M
Total Debt (Recent Filing)$104.52M
Price to Earnings (P/E)―
Beta1.76
Next Earnings
May 06, 2026EPS Estimate
-0.78Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.84
Shares Outstanding18,311,626
10 Day Avg. Volume109,868
30 Day Avg. Volume190,724
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.44
Price to Sales (P/S)0.47
P/FCF Ratio-1.20
Enterprise Value/Market Cap1.91
Enterprise Value/Revenue1.23
Enterprise Value/Gross Profit3.13
Enterprise Value/Ebitda-2.40
Forecast
1Y Price Target
$10.50Price Target Upside156.10% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-2.69
Revenue Forecast (FY)$126.63M
Bulls Say, Bears Say
Bulls Say
Clinical OutcomesDemonstrated reductions in central line-associated bloodstream infections linked to Tablo-driven ultrafiltration monitoring may encourage hospitals to expand in-house dialysis programs.
Cost SavingsLower supplies cost per treatment versus third-party contractors could make in-house Tablo adoption economically attractive for high-volume hospitals.
Recurring Revenue And MarginsGrowing consumables and service revenue, along with a higher consumables mix and operational improvements, may boost gross margins and stabilize recurring cash flows.
Bears Say
Cash Burn And Financing RiskUse of cash during the period increases the likelihood of future external financing, which could dilute shareholders or raise leverage if borrowing is required.
Operational Staffing RiskHigh nurse turnover and elevated staffing demands at hospitals may force reductions in non-critical care dialysis hours, limiting potential uptake of Tablo systems.
Profitability PressureA larger-than-expected adjusted loss per share driven by higher general and administrative expenses signals near-term profitability pressure that could weigh on the stock.
Outset Medical News
OM FAQ
What was Outset Medical’s price range in the past 12 months?
Outset Medical lowest stock price was $3.00 and its highest was $21.98 in the past 12 months.
What is Outset Medical’s market cap?
Outset Medical’s market cap is $76.82M.
When is Outset Medical’s upcoming earnings report date?
Outset Medical’s upcoming earnings report date is May 06, 2026 which is in 27 days.
How were Outset Medical’s earnings last quarter?
Outset Medical released its earnings results on Feb 11, 2026. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.674 by -$0.166.
Is Outset Medical overvalued?
According to Wall Street analysts Outset Medical’s price is currently Undervalued.
Does Outset Medical pay dividends?
Outset Medical does not currently pay dividends.
What is Outset Medical’s EPS estimate?
Outset Medical’s EPS estimate is -0.78.
How many shares outstanding does Outset Medical have?
Outset Medical has 18,311,626 shares outstanding.
What happened to Outset Medical’s price movement after its last earnings report?
Outset Medical reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.674. Following the earnings report the stock price went down -16.3%.
Which hedge fund is a major shareholder of Outset Medical?
Currently, no hedge funds are holding shares in OM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Outset Medical Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (156.10% Upside)
$10.50 (156.10% Upside)
Blogger Sentiment
Bullish
OM Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 36.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $193.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-62.53%
12-Months-Change
Fundamentals
Return on Equity
-54.99%
Trailing 12-Months
Asset Growth
-4.10%
Trailing 12-Months
Company Description
Outset Medical
Outset Medical, Inc., a medical technology company, develops a hemodialysis system for dialysis. It provides the Tablo Hemodialysis System, which comprises a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings. The company was formerly known as Home Dialysis Plus, Ltd. and changed its name to Outset Medical, Inc. in January 2015. Outset Medical, Inc. was incorporated in 2003 and is headquartered in San Jose, California.
OM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlighted clear operational and financial progress: revenue growth, material gross margin expansion, reduced operating expenses and cash burn, a strengthened balance sheet, strong customer satisfaction, and strategic momentum from FDA clearance of a cyber-hardened next-generation Tablo. Lowlights include lingering net losses, continued cash use (though improved), manufacturing under-absorption headwinds, product revenue timing variability, and long enterprise sales cycles. On balance, the positives around margin expansion, cost discipline, product leadership (cyber clearance), and improved cash runway outweigh the remaining challenges.View all OM earnings summariesOM Revenue Breakdown
47.04% Consoles
32.37% Consumables
20.59% Service and other revenue
OM Stock 12 Month Forecast
Average Price Target
$10.50
▲(156.10% Upside)
Technical Analysis
Ownership Overview
3.90% Insiders
22.18% Mutual Funds
31.60% Other Institutional Investors
33.13% Public Companies and
Individual Investors